Energy Nexus, Volume 6, 100062
The Journal of Climate Change and Health,
2022,
100148
Current Developments in Nutrition, Volume 6, Issue 8, August 2022, nzac103
eClinicalMedicine, Volume 48, June 2022
Background: Abatacept is a selective T-cell costimulation modulator approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Reports were recently published on hepatitis B virus reactivation (HBVr) in patients who were treated with abatacept. However, the literature is limited to case reports and series, and no study has investigated the relationship between HBVr and abatacept using extensive population-based databases.